Navigation Links
Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
Date:9/15/2009

inties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
2. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
3. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
6. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
9. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
10. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
11. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Dec. 3 ParagonRx, a Delaware-base...gement and optimal medication use, will host a fre... guidance on REMS - Risk Evaluation Mitigation Str...ecycle management. Dr. Gary Slatko, chief medical...sk management programs, will lead the one-hour pro...
(Date:12/3/2009)... Cardium Therapeutics (NY...ned subsidiary, Tissue Repair Company, submitted a.... Food and Drug Administration (FDA) seeking marke...didate based on positive data from the Company,s r... Today,s submission with the FDA covers Excellagen...
(Date:12/3/2009)...lif., Dec. 3 Each year, ... United States (U.S.) and Europe participate in th...ry experience under renowned faculty members at th...holars - past, present and future - will have excl...y at www.amgenscholars.com . ,, "The new Web ...
Breaking Medicine Technology:Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 2New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 1Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 11Maternal HIV 1 treatment protects against transmission to newborns 59640 1Maternal HIV 1 treatment protects against transmission to newborns 59640 2University of the Basque Country study on proteins related to Alzheimers 10397 1University of the Basque Country study on proteins related to Alzheimers 10397 2
...LES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corpora...gaged in the,development and commercialization of ... from the six-month, open-label extension,of its c... in ALS,volunteers. While the clinical trial was n...e three times daily appeared to be safe,and well-t...
...e Netherlands, June 27, 2007-Organon, the human,he...day that two,out of three Phase III clinical trial...g-acting fertility hormone, have reached,their ran...ew recombinant fertility hormone. It is,the first ...cular,stimulant or SFS) of which, due to its long ...
Other Medicine Technology:CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 2CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 3CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 5Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
(Date:12/3/2009)..., , SOUTHBRIDGE, Mass., Dec. 3 /PRNewswire/... approval to treat its first patients, Harrington ...t seeing patients immediately," said Diane Becquar..., The approval was granted today by the Massachu...ty and quality review of the facility. ,, The ...
(Date:12/3/2009)..., , BEIJING, Dec. 3 /PRNewswire-Asia/...enefits, ginger, one of the most important ingredi...in China during this flu season. , The ti... supply shortages,effecting upward price pressure...potential repeat of the current demand hysteria ov...
(Date:12/3/2009)..., , SILVER SPRING, Md., Dec. 3 /PRNewsw...g a health care system that ensures affordable, qu...on urges all Americans to contact their representa...h care reform. ,, See video from ANA at: http:...dvocating for a health care system that focuses on...
(Date:12/3/2009)...Roles of aggressor, victim often play out at schoo...c. 3 (HealthDay News) -- School bullies are also l... according to an Italian study that included 195 c...rticipants -- all with a sibling no more than four...ether they bullied or were bullied at school or at...
(Date:12/3/2009)...Finding could aid in eventual development of scree...DAY, Dec. 3 (HealthDay News) -- New research point...amin D and heart disease. , People with high bl...itamin D activation in the body were found to be t...e congestive heart failure, the study found. , ...
Breaking Medicine News(10 mins):Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:VIDEO from Medialink and the American Nurses Association (ANA): American Nurses Association Urges All Americans to Take Part in Health Care Reform Debate 2Health News:Bullies May Intimidate Siblings, Too 2Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2
...anizations are turning to Amalga to connect hospit...h centers., REDMOND, Wash., June 24 To improve t...to medically underserved,D.C. residents, the Distr... hospitals and six community-based health,centers ...
...COUVER, June 24 /PRNewswire-FirstCall/ - Beeston E...BB: BESE) announces that it completed,drilling on ... from,Candorado Operating Company Ltd. (TSX Ventur... copper-gold deposits., The Company is carrying o...
...New evidence-based guidelines address the preventi...ulations and reinforce recommendations related to ... as a supplement in the June issue of CHEST , the...ice Guidelines, Eighth Edition was developed by an...
...cuity,s Release of PriceAdvisor Combats Ineffectiv...action & Improve Revenue Projection and Recovery ...HILLS, Ill. and DUBLIN, Ireland, June 24 /PRNewswi...ology ("Peer,Reviewed by HFMA") and services, toda...
...tery shoppers allow providers to compare real expe...pectations., DALLAS, June 24 Mystery shopping go... why patients leave -- sometimes without,ever meet...come patients because they dismiss a healthcare or...
...3M Health Care today announced the launch of the 3...cal mask to meet the needs of clinicians seeking a...urgical mask incorporates proprietary filtration m... design, the 3M Filtron 1900 surgical mask provide...
Other Medicine News:Health News:District of Columbia Primary Care Association Selects Microsoft Amalga to Improve Patient Care for the Underserved 2Health News:District of Columbia Primary Care Association Selects Microsoft Amalga to Improve Patient Care for the Underserved 3Health News:Beeston completes drilling on Bluff Lake property, 100 Mile House 2Health News:New blood clot guidelines for pregnant women 2Health News:New blood clot guidelines for pregnant women 3Health News:New blood clot guidelines for pregnant women 4Health News:Concuity Announces the Availability of PriceAdvisor 2Health News:Concuity Announces the Availability of PriceAdvisor 3Health News:Concuity Announces the Availability of PriceAdvisor 4Health News:New White Paper from The Beryl Institute: 'Mystery Shopping the Patient Experience' 2Health News:3M Health Care launches new high-performance surgical mask 2
Medium Clip Appliers
Li Brand™ Surgical Hemostat
The 2201
No Scalpel Vasectomy Hemostat
Medicine Products: